Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The first patient has been dosed using new drug PORT-2 in Oxford, which hopes to improve treatment options for melanoma and Non-Small Cell Lung Cancer (NSCLC) and resensitise patients with checkpoint therapy-resistant tumours

Medication being administered to a patient via IV

The IMP-MEL clinical trial has begun with its first patient being dosed with the new drug PORT-2 today in Oxford. The Oxford-led study is investigating the tolerability and efficacy of PORT-2, a drug that was developed to target iKT and trigger a cancer-specific B and T-cell response to tumours.

The IMP-MEL study is expected to enroll 100 patients in Oxford and other centres, and will evaluate PORT-2 both as a monotherapy and in combination with approved PD-1 inhibitor drug Keytruda in the treatment of Melanoma and Non-Small Cell Lung Cancer (NSCLC).

Read the full story on the Oxford Cancer website.

Similar stories

NHS garden in full bloom at RHS Chelsea Flower Show

The sun was shining for the RHS Chelsea Flower show press day earlier this week. One garden in particular bloomed particularly brightly, with the 'Finding Our Way: An NHS Tribute Garden' getting plenty of attention.

University of Oxford launches Podium Analytics Institute for Youth Sports Medicine and Technology

Oxford University has been selected as the home of the new Podium Analytics Institute for Youth Sports Medicine and Technology. This will be the world’s first academic Institute focused on young athletes’ safety and lifelong health and will combine Oxford’s longstanding tradition in sports and education with the very best of science, medicine, and technology.

QCovid highly commended for ‘best use of technology in Patient Safety’ at the 2021 HSJ Patient Safety Awards

Professor Julia Hippisley-Cox and her team in Nuffield Department of Primary Care Health Sciences have been Highly Commended in the ‘Best use of technology in Patient Safety’ category for the QCovid risk calculator at this year’s Health Service Journal Patient Safety Awards.

New guidelines to improve reporting standards of studies that investigate causal mechanisms

Researchers in the Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS) have developed a new set of guidelines for reporting mediation analyses in health research.

Prestigious award for Oxford professor's diabetes work

A University of Oxford professor has been awarded the 2021 EASD-Novo Nordisk Foundation Prize for Excellence for his decades of effort to understand, prevent and combat type 1 diabetes.